Want to see DCTH full AI Analyst Report?
DCTH Stock Chart & Stats
$12.22
-$0.28(-2.29%)
At close: 4:00 PM EDT
$12.22
-$0.28(-2.29%)
Day’s Range― - ―
52-Week Range$8.12 - $17.42
Previous Close$12.03
Volume439.54K
Average Volume (3M)415.04K
Market Cap
$594.74M
Enterprise Value$407.16
Total Cash (Recent Filing)$95.90M
Total Debt (Recent Filing)$2.46M
Price to Earnings (P/E)1558.2
Beta1.69
Next Earnings
Nov 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding34,698,795
10 Day Avg. Volume319,378
30 Day Avg. Volume415,038
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.50Price Target Upside92.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.15
Revenue Forecast (FY)$106.44M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And High Gross MarginsHEPZATO-driven growth and gross margins above 85% indicate strong product economics as utilization expands. Sustained volume growth could improve operating leverage and support a durable transition from commercialization investment toward consistent profitability.
Strong Liquidity And Minimal LeverageA substantial cash balance, no debt, and positive operating cash flow give Delcath flexibility to fund clinical programs, commercial expansion, and manufacturing without immediate financing dependence. This strengthens resilience while the business scales.
Clinical Evidence Supports AdoptionPublished CHOPIN evidence that supports improved response rates may strengthen physician confidence and broaden treatment adoption. If replicated in practice, the data can reinforce HEPZATO's clinical differentiation and support longer-term center utilization.
Bears Say
Profitability Remains FragileThe return to a quarterly loss and sharp EBITDA decline show that revenue growth has not yet translated into durable earnings. Higher operating costs and possible spending volatility could delay sustained profitability even with strong gross margins.
Commercial And Clinical Execution RiskSlower center activation limits near-term treatment capacity, while weak mCRC enrollment can delay evidence generation and future indications. These execution gaps may constrain the pace of market expansion and increase the time required to realize pipeline value.
Reimbursement And Capacity ConstraintsReimbursement barriers in Europe can restrict international growth, while seasonal scheduling and limited trained-team capacity can suppress procedure volumes. These structural commercial frictions may make revenue less predictable and slow broader adoption.
Delcath Systems News
DCTH FAQ
What was Delcath Systems, Inc.’s price range in the past 12 months?
Delcath Systems, Inc. lowest stock price was $8.12 and its highest was $17.42 in the past 12 months.
What is Delcath Systems, Inc.’s market cap?
Delcath Systems, Inc.’s market cap is $594.74M.
When is Delcath Systems, Inc.’s upcoming earnings report date?
Delcath Systems, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Delcath Systems, Inc.’s earnings last quarter?
Delcath Systems, Inc. released its earnings results on Aug 06, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.089 by $0.159.
Is Delcath Systems, Inc. overvalued?
According to Wall Street analysts Delcath Systems, Inc.’s price is currently Undervalued.
Does Delcath Systems, Inc. pay dividends?
Delcath Systems, Inc. does not currently pay dividends.
What is Delcath Systems, Inc.’s EPS estimate?
Delcath Systems, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Delcath Systems, Inc. have?
Delcath Systems, Inc. has 34,698,795 shares outstanding.
What happened to Delcath Systems, Inc.’s price movement after its last earnings report?
Delcath Systems, Inc. reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.089. Following the earnings report the stock price went up 22.486%.
Which hedge fund is a major shareholder of Delcath Systems, Inc.?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (92.31% Upside)
$23.50 (92.31% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 185.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.23%
Trailing 12-Months
Company Description
Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DCTH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$23.50
▲(92.31% Upside)
Technical Analysis
Ownership Overview
21.68% Insiders
7.27% Mutual Funds
21.08% Other Institutional Investors
40.67% Public Companies and
Individual Investors